Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Algik is a brand of non-prescription analgesic and antipyretic medications developed and marketed by Laboratórios Azevedos in Portugal. The brand encompasses several distinct small molecule formulations designed for the treatment of mild to moderate pain and fever. These include Ibuprofeno Algik (ibuprofen, available as an oral suspension and 400 mg tablets), Paracetamol Algik (paracetamol, available as an oral solution), and Paracetamol + Cafeína Algik (a combination of paracetamol and caffeine, available as a powder for oral solution). The active ingredients primarily function by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the synthesis of inflammatory prostaglandins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Algik.